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Effect of lovastatin on small GTP binding proteins and on (HMG CoA) reductase inhibitor in diabetic nephropathy
TGF-b1 and fibronectin expression. We have shown that lova- are mostly of short duration and in small populations of
statin, an inhibitor of 3 hydroxy-3-methylglutary coenzyme A patients [1]. The role of HMG CoA reductase inhibitor in(HMG CoA) reductase, delays development and progression
experimental diabetes remains incompletely understood.of diabetic nephropathy in streptozotocine-induced diabetic rats
Recently, we demonstrated in streptozotocin (STZ)-through suppression of glomerular transforming growth factor
(TGF)-b1 mRNA expression. We have also shown that lova- induced diabetic rats that lovastatin significantly sup-
statin suppresses both control and high glucose (HG)-induced pressed glomerular transforming growth factor (TGF)-b1
TGF-b1 and fibronectin mRNA expression and protein synthe- expression in 4 days and urinary albumin excretion in 4sis by rat mesangial cell (RMC) and that this down-regulation
weeks; it also reduced glomerular volume in 2 weeksby lovastatin is reversed by mevalonate. It was postulated that
after induction of diabetes mellitus [2]. In this study,this down-regulation may be linked to signaling of small gua-
nine triphosphate (GTP)-binding proteins and mediated by the lovastatin suppressed serum cholesterol level in diabetic
limitation of isoprenoids such as farnesylpyrophosphate (FPP) rats only after 6 months, suggesting that lovastatin may
and geranylgeranylpyrophosphate (GGPP) in RMC. To deter- have renal protective effect independent of lipid low-mine the isoprenoid and small GTP-binding proteins involved
ering action. Park et al [3] found that lovastatin reducedin TGF-b1 and fibronectin expression, FPP or GGPP was
mesangial proliferation and glomerular macrophage in-added alone or in combination to RMC treated with lovastatin
cultured under normal or high glucose condition. Suppression filtration before any increase in extracellular matrix in
of TGF-b1 and fibronectin expression by lovastatin was re- nephrotic rats. These observations suggest that lovastat-
versed effectively when GGPP was added alone. Partial rever-
in’s effect on albuminuria and glomerular hypertrophysal of lovastatin effect on fibronectin and TGF-b1 expression
may be related to modulation of early cellular events inwas found when FPP was added alone. Adding both GGPP
and FPP resulted in complete reversal of lovastatin effect on a diabetic kidney.
fibronectin but not TGF-b1 suggesting that fibronectin and
TGF-b1 are regulated differently. Furthermore, luciferase ac-
tivity of RMC cotransfected with fibronectin promoter reporter CELLULAR EFFECTS OF HMG CoA
system and plasmid-expressing C3 exoenzyme (a specific inacti- REDUCTASE INHIBITOR
vator of Rho family GTP binding proteins, pEFC3) was com-
HMG CoA reductase is a rate-limiting enzyme in apletely suppressed when compared with RMC cotransfected
with empty vector, pEF. Because geranylgeranylation is usually cholesterol biosynthetic mevalonate pathway (Fig. 1).
involved in post-translational modification and membrane tar- HMG CoA reductase inhibitor has been shown to pro-
geting of Rho family small GTP binding proteins, these data duce various effects at the cellular level: suppression of
indicate that Rho family small GTP-binding proteins rather
the expression of chemokines [3] and cytokines [2, 4],than Ras family small GTP binding proteins may play a key
induction of apoptosis of mesangial cells [5], inhibitionrole in the TGF-b1 and fibronectin expression in RMC.
of cell proliferation [6], interference with intracellular
signaling [7], reduction of extracellular matrix (ECM)
production [8] and modulation of ECM protein degrada-Although hyperlipidemia is considered a potential risk
tion system [9].factor for renal fibrosis, the clinical effect of lipid low-
From the mevalonate pathway, several isoprenoids areering on the prevention of diabetic nephropathy remains
produced as an intermediate stage, including farnesyl-unclear. Clinical studies investigating the renal protec-
pyrophosphate (FPP) and geranylgeranylpyrophosphatetive effect of 3 hydroxy-3-methylglutary coenzyme A
(GGPP) as shown in Fig. 1. These isoprenoids are en-
rolled in post-translational modification [10] and mem-
Key words: HMG CoA reductase inhibitor, mesangial cell, isoprenoids. brane localization of small guanine triphosphate (GTP)
binding proteins such as Ras and Rho family proteinsÓ 2000 by the International Society of Nephrology
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Ras and/or Raf resulting in triggering of Raf-MEK1-
ERK cascade [13, 14]. Some evidence suggests that Rho
family small GTP binding proteins are involved in PKC
activation [15] and translocation to plasma membrane
[16]. However, the precise signaling network between
Rho family GTP binding proteins and an individual iso-
form of PKC still remains to be elucidated.
LOVASTATIN DOWN-REGULATES
EXPRESSION OF TGF-b1 IN RAT
GLOMERULI AND MESANGIAL CELLS
We demonstrated that the glomerular TGF-b1 expres-
sion in STZ-induced diabetic rats was suppressed by
lovastatin at day 2 after treatment [4] and this effect by
lovastatin was sustained for up to 3 months [2]. Increased
TGF-b1 expression by HG (30 mmol/L) in rat mesangialFig. 1. Cholesterol biosynthetic pathway. HMG CoA reductase is a
rate-limiting enzyme in this pathway and converts HMG CoA to meva- cells (RMC) was also suppressed by lovastatin [2]. There-
lonate. Lovastatin blocks this step by the inhibition of this enzyme. fore, it appears that the suppressive effect of lovastatin
Various isoprenoids such as DPP, IPP, GPP, FPP, and GGPP are
on the HG-induced glomerular TGF-b1 expression isproduced from mevalonate. Cholesterol is synthesized from FPP through
squalene. FPP is responsible for the post-translational modification and through a direct effect at cellular level rather than any
membrane targeting of Ras protein, whereas GGPP is responsible for cholesterol lowering effect. Although the intracellular
those of Rho family small GTP-binding proteins.
signaling pathway responsible for TGF-b1 expression
induced by HG is not yet clearly defined, it appears that
Rho family small GTP binding protein(s) is involved
in this pathway. As shown in Fig. 3, the addition of[11]. Localization to plasma membrane and activation
mevalonate or GGPP but not FPP to the lovastatin-of the small GTP binding proteins are followed by intra-
treated RMC cultured under control or HG reversed thecellular signaling and activation of various transcription
suppressive effect of lovastatin on TGF-b1 expression.factors. The treatment with HMG CoA reductase inhibi-
TGF-b1 expression is up-regulated by HG in both intor therefore may reduce the concentration of isopren-
vivo and in vitro experiments but it is still unclear as tooids intracellularly, thus reducing functional small GTP
what transcription factor(s) is responsible for the up-binding proteins and interference with intracellular sig-
regulation. Three different AP-1 binding sites are locatednaling. As shown in Fig. 2, activation of Ras protein is
on the TGF-b1 promoter region; they are the majorresponsible for activation of a mitogen-activated protein
elements responsible for the tetradecanoylphorbol ace-kinase (MAPK) pathway cascade (Raf-MEK1-extracel-
tate (TPA) activation and TGF-b1 autoinduction [17].lular regulated kinase [ERK]). Intracellular signaling
Other transcription factor binding sites including Sp1,pathways induced by Rho family proteins activate stress-
CRE, NF-kB, and Egr-1 are also found in the TGF-b1activated protein kinase/c-Jun N-terminal protein kinase
promoter region. Other evidence suggests that Sp1 is re-(SAPK/JNK) and p38 MAPK. These kinases also acti-
sponsible for the expression of TGF-b1 and TGF-b3 [18].vate various transcription factors including Elk1, cyclic
A putative glucose responsible element (GLURE), CAC
adenosine monophosphate (cAMP) 2 responsible ele- GTG was also found in the promoter region (21040 ,
ment binding protein (CREB), nuclear transcription fac-
21009) of human TGF-b1 gene as was shown in mouse
tor (ATF)-2, AP-1, NF-kB, and Myc (Fig. 2). Therefore, TGF-b1 gene [19].
the decrease in membrane bound small GTP binding SAPK/JNK or p38 MAPK signaling pathways are pre-
proteins reduces expression and activation of various sumably activated by Rho family small GTP-binding pro-
transcription factors leading to down-regulation of vari- teins rather than Raf-MEK-ERK pathway activated by
ous gene expression. Although the expression of various Ras protein may regulate TGF-b1 expression because
genes are regulated by inhibitor of HMG CoA reductase the SAPK/JNK and p38 MAPK cascades also activate
through small GTP binding proteins, the precise signal- AP-1. In addition, ERK MAPK can be activated by Rho A
ing pathways responsible for the expression of genes en- through unspecified signaling pathway. Therefore, it is
coding TGF-b and extracellular matrix (ECM) proteins suggested that lovastatin suppresses expression of TGF-b1
induced by high glucose (HG) are not defined clearly. induced by control or HG through decreased activation
Another important intracellular signaling molecule ac- of the transcription factors as a result of the reduction
tivated by HG is protein kinase C (PKC) [12]. It has of functional Rho family small GTP-binding proteins on
plasma membrane.been established that certain isoforms of PKC stimulate
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Fig. 2. Major intracellular signaling path-
ways mediated by small GTP-binding pro-
teins. Three different MAPK signaling path-
ways named ERK pathway (Ras ! Raf !
MEK1/2 ! ERK1/2), SAPK/JNK pathway
(MEKK1 ! SEK/MKK4 ! SAPK/JNK), and
p38 pathway (TAK1 ! MKK3/6 ! p38) are
well established and involved in the intracellu-
lar signaling of the small GTP-binding pro-
teins. From these MAPK pathways, various
transcription factors such as Elk1, ATF-2
(CREB), AP-1, NF-kB, and Sp1 are activated
and start the transcription of target genes.
Fig. 4. Effect of FPP and GGPP on the expression of fibronectin
mRNA. After 4 h of treatment with liposome containing FPP and/or
GGPP, cells were washed twice with media without serum, and incu-
bated another 24 h under control or HG conditions with 10 mmol/L of
lovastatin. Total RNA was isolated and Northern blot analysis per-
formed for fibronectin mRNA.
Fig. 3. Effect of FPP and GGPP on the expression of TGF-b1 mRNA.
FPP (15 mmol/L) and GGPP (15 mmol/L) were mixed alone or together
with cationic liposome and added in rat mesangial cell culture treated
Rho family small GTP-binding protein(s) rather thanwith lovastatin under controlled or HG conditions. After 4 h of treat-
ment with liposome containing FPP and/or GGPP, cells were washed Ras. Essig et al [9] reported that lovastatin modulated the
twice with media without serum and incubated another 24 h under plasminogen activator/plasmin system of rat proximal
control or HG with 10 mmol/L of lovastatin. Total RNA was isolated
tubular cells both in vivo and in vitro. In the in vivo study,and Northern blot analysis for TGF-b1 and GAPDH was carried out.
lovastatin induced an increase in activity and amount of
tPA and uPA, and a decrease in plasminogen activator
inhibitor-1 (PAI-1). A similar result was obtained from
EFFECTS OF LOVASTATIN ON the cultured primary renal proximal tubular cells. In the
ECM METABOLISM cell culture study, however, no uPA activity was detected.
Changes in plasminogen activator/plasmin system by lo-Recent studies suggested that lovastatin and other in-
hibitors of HMG CoA reductase reduce ECM accumula- vastatin were reversed by mevalonate and GGPP and
by treatment with C3 exoenzyme, an inactivator of Rhotion through two possible ways; the suppression of ECM
synthesis and the enhancement of ECM degradation. family GTP-binding proteins.
We have also demonstrated that lovastatin suppressedNishimura et al [8] reported that pravastatin inhibited
fetal calf serum–stimulated type IV collagen secretion fibronectin mRNA and protein synthesis induced by HG
in RMC. This lovastatin effect was reversed by the addi-and mRNA expression by mesangial cells and that
GGPP and mevalonate reversed the effects of prava- tion of GGPP (Fig. 4) as well as mevalonate [2]. Addition
of FPP allowed only partial reversion of suppressive ef-statin nearly completely. The pravastatin effects on type
IV collagen secretion and expression may depend on fect of lovastatin on fibronectin expression. By adding
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lovastatin exerts its renal protective effects in experimen-
tally induced diabetes through inactivation of Rho family
small GTP-binding proteins.
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